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Abstract 
 
Goblet cell carcinomas (GCC) are a rare, aggressive sub-type of appendiceal tumours with 
neuroendocrine features, and controversy exists with regards to therapeutic strategy. We undertook a 
retrospective review of GCC patients surgically treated at two tertiary referral centres. Clinical and 
histopathological data were extracted from a prospectively maintained database. Survival analyses 
utilised Kaplan-Meier methodology. Twenty-one patients were identified (9 females). Median age at 
diagnosis was 55years (range 32-77). There were 3, 6 and 9 grade 1, 2 and 3 tumours, respectively. 
One, 10, 5 and 5 patients had stage I, II, III and IV disease at diagnosis, respectively. There were 8, 10 
and 3 Tang class A, B and C tumours, respectively. Index operation was appendectomy (n=12), right 
hemicolectomy (n=6) or resections including appendix/right colon, omentum and the gynaecological 
system (n=3). Eight patients underwent completion right hemicolectomy. Surgery for recurrence 
included small bowel resection (n=2), debulking with peritonectomy and heated intraperitoneal 
chemotherapy, and hysterectomy and bilateral salpingo-oophorectomy (all n=1). Median follow-up 
was 30months (range 2.5-123). One-, 3- and 5-year OS was 79.4%, 60% and 60%, respectively. Mean 
OS (1-, 3-, and 5-year OS) for Tang class A, B and C tumours were 73.1months (85.7%, 85.7%, 
51.4%), 83.7months (all 66.7%) and 28.5months (66.7%, 66.7%, not reached), respectively. 
Chromogranin A/B and 68Ga-DOTATATE PET/CT were not useful in follow-up, but CEA, CA 19-9, 
CA 125 and 18F-FDG PET/CT identified tumour recurrence. GCC must be clearly discriminated from 
relatively indolent appendiceal neuroendocrine neoplasms. 
18
F-FDG PET/CT and CEA/CA19-9/CA 
125 are useful in detecting recurrence of GCC.  
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Introduction 
 
Initially termed ‘goblet cell carcinoids’ [1], goblet cell carcinomas (GCC) are a rare sub-type of 
neoplasm arising from the appendix, accounting for less than 14% of all appendiceal tumours [2]. 
Whilst an ‘intermediate’ phenotype with regards to aggressiveness between appendiceal 
neuroendocrine neoplasms (ANEN) and adenocarcinoma has been described [3,4], their incidence of 
0.05/100,000/year [5] renders clinical experience limited. A median age at diagnosis of 58.9years and 
no significant gender disparity have been reported in a systematic review of 600 patients [6]. 
Historically often regarded as part of the spectrum of neuroendocrine neoplasms, GCC do indeed 
display a degree of neuroendocrine differentiation with expression of chromogranin A and B, 
synaptophysin, and allelic loss of chromosomes 11q, 16q and 18q has been observed in GCC, similar 
to NEN arising from the jejunum/ileum [7]. However, their proliferation index as measured by Ki67 is 
often much higher than in intestinal NEN [8] and GCC display a more aggressive biology to the 
extent that they must be clearly delineated from NEN [4,9]. Such divergences in clinical behaviour are 
evident in the 5-year disease specific survivals with ANEN exceeding 90%, whereas in GCC these 
range between 58-81% [10–12]. Immunohistochemical distinction between the mucin-secreting GCC 
and ANEN may manifest as the stronger expression of CEA, CDX-2, CAM5.2 and cytokeratin (CK) 
in the former relative to the latter [13]. In other histological analyses, an appreciable decrement in the 
expression of neuroendocrine markers in metastatic deposits of GCC in some patients has been 
reported [14]. Although both ANEN and GCC are in general diagnosed incidentally at appendectomy, 
patients with GCC may present symptomatic and at advanced tumour stages in 10-63% of cases 
[4,15].  
The TNM staging of GCC follows the same system for ANEN as proposed by the Union Contre le 
Cancer/American Joint Committee on Cancer (UICC/AJCC) [4] (Table 1), which is supported in the 
consensus guidelines of the European Neuroendocrine Tumor Society (ENETS). The grading system 
replicates that of the ENETS/World Health Organization (WHO) system based on Ki67 index, i.e. 
grade 1 = <2%, grade 2 = 3-20%, and grade 3 >20% [16]. The TNM staging is a significant 
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prognosticator, with 5-year overall survivals in stage I, II, III and IV disease being 100%, 76%, 22% 
and 14%, respectively, reported in a retrospective series of 57 GCC patients [17]. A recently proposed 
histo-morphological classification by Tang et al. [15] classifies GCC as typical GCC and 
adenocarcinoma ex-GCC (Table 2). Typical GCC are deemed as ‘group A’ and display well defined 
goblet cell morphology without significant atypia. The latter group may be sub-divided into group B 
or group C, which demonstrate large irregular clusters of goblet or signet cell-type cells with 
destruction of the appendiceal wall, or exhibit poor differentiation, respectively. This classification 
has been shown to correlate with prognosis in both the original report and a recent case series 
[15,18,19]. For example, in the original report of Tang, et al. [15], 5-year overall survivals in Type A, 
B and C GCC were 96%, 73% and 14%, respectively.   
Regarding treatment, controversy surrounds the optimal approach for small (<1cm), non-metastatic 
GCC, specifically whether appendectomy is sufficient or an oncologic right-hemicolectomy is 
mandated [9,20–22]. The literature do not support any specific size cut-off, although some studies 
have suggested 10mm as an appropriate arbiter of further resection [23]. However, <1cm tumours are 
rarely encountered, and thus more aggressive therapy must often be considered utilising surgical 
and/or medical modalities. Right hemicolectomy is advocated as the standard surgical approach by the 
European Neuroendocrine Tumor Society (ENETS) and North American Neuroendocrine Tumor 
Society (NANETS), although less than half of patients in population-based registries were reported to 
undergo this [23]. The ENETS guidelines from 2012 advocated a completion right hemicolectomy 
within 3 months of appendectomy, and recommend ongoing 3-month interval staging for follow-up, 
although the optimal imaging modality is not clear [4]. Somatostatin receptor-targeted imaging loses 
sensitivity with increasing proliferation and thus loss of neuroendocrine differentiation, whereas 18F-
FDG PET may have more clinical utility. Regarding biochemical tests, use of the archetypal 
neuroendocrine markers chromogranins A and B is not recommended, and although CEA, CA 19-9 
and CA 125 may be clinically useful, there is no definitive role [4]. Selected patients with peritoneal 
dissemination may be considered for cytoreductive surgery and chemotherapy, or peritonectomy with 
hyperthermic intra-peritoneal chemotherapy (HIPEC), whilst the majority of patients with metastatic 
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disease are treated with chemotherapy regimens akin to those utilised in colonic adenocarcinoma, i.e. 
with regimens based on 5-fluorouracil (5-FU).  [9].  
Here, we present our institutional experience with a cohort of 21 patients with GCC, all of which 
underwent surgical treatment as a component of a multimodal management strategy. Our aim was to 
identify clinically useful factors in the diagnosis and follow-up of GCC, and also to examine the role 
of aggressive surgical intervention in patients with GCC. 
 
Patients and methods 
 
We undertook a retrospective case review of individual patients treated for GCC at our centres – St 
Mark’s Hospital London (London North West Healthcare NHS Trust), and Imperial College London 
Healthcare NHS Trust, which is an ENETS Centre of Excellence for Neuroendocrine Tumours – 
between August 2006 and January 2017. The data collected from 2010 onwards were extracted from a 
prospectively maintained data base for neuroendocrine neoplasms. For inclusion in our study, patients 
had to be over 18 years of age, with histologically confirmed GCC and underwent surgical treatment. 
We are unaware of any patients with GCC that were not surgically treated. Individual patient cases 
were identified, with basic demographic, clinical and histopathological data extracted. Tumour 
grading was as per the ENETS guidelines [16], with grade 1, 2 and 3 defined as Ki67 <2%, 3-20% 
and >20%, respectively. Staging was as per the UICC/AJCC TNM classification (Table 1 [4]). 
Histological reports were retrieved to assign ‘Tang’ classification (Table 2) and reviewed by two 
dedicated NEN pathologists. The follow-up regime for our patients comprised: cross sectional 
imaging (CT, MRI liver), functional imaging (68Ga-DOTATATE PET/CT, 18F-FDG PET/CT), tumour 
markers (chromogranin A and B, CEA, CA125, and CA19-9). The type of modality used was tailored 
to the individual patient (e.g. 68Ga-DOTATATE PET/CT for G1 tumours only and 18F-FDG PET/CT 
for G2 and G3). No other imaging modalities were used. Patients were followed up at 3-6 monthly 
intervals, which has been the institutional protocol since the beginning of the study period.  
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Kaplan-Meier methodology was utilised in the analysis of survival functions. Statistical calculations 
utilised R software, v3.3.2. The study was approved by the institutional review board at Imperial 
College London (REC07/MRE09/54). Consent was obtained from each patient after full explanation 
of the purpose and nature of all procedures used.  
 
Results 
 
Within the study period we identified 147 patients with appendiceal tumours (data not presented here) 
[24]. Of them, 21 had GCC (9 female, 12 male). The median age at diagnosis was 55 years (range 32-
77). Regarding UICC/AJCC tumour stage, there were: 1 stage I, 10 stage II, 5 stage III and 5 stage IV 
tumours. Tumour grade was available for 18 patients, with 3 G1, 6 G2 and 9 G3 tumours. Tang 
classification was available for all patients – there were 8, 10 and 3 patients with Tang type A, B and 
C tumours, respectively. In 10 patients, the primary tumour was located at the base of the appendix, 
with 5 in the body of the appendix, 3 at the appendiceal tip, and in 3 the location of the tumour was 
not reported. Basic clinicopathological characteristics are displayed in Table 3. The diagnosis of GCC 
was made only post-operatively in all patients, as is typical of this tumour type. Patients were 
primarily operated on for suspected appendicitis, due to lower abdominal pain with/without pyrexia, 
although one patient additionally had sub-acute bowel obstruction of initially uncertain aetiology. 
Patients found at index operation to have either large tumours and/or tumours displaying evidence of 
disease spread underwent operations other than simple appendectomy, i.e. right hemicolectomy or 
multivisceral resections, with the diagnosis of GCC evident on histology of resected tissues.   
Regarding index operations, 12 underwent appendectomy, 6 underwent right hemicolectomy and 3 
had multivisceral resections of the lower gastrointestinal and gynaecological systems (Table 4). For 
the latter, these were: appendectomy + oophorectomy + omentectomy (n=1), appendectomy + 
hysterectomy + oophorectomy + omentectomy (n=1), and right hemicolectomy + omentectomy + 
uterine resection (n=1).  
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Following index operation, 6 patients received adjuvant cytotoxic chemotherapy with 5-FU-based 
regimens analogous to those for colorectal carcinoma. Specifically, these patients were treated in 
accordance with protocol for high-risk Dukes’ B colorectal carcinoma. The regimen utilised was 
CAPOX, i.e. capecitabine (which is metabolised to 5-FU) and oxaliplatin. This was administered in 
21-day cycles.  
 
Some patients underwent a further ‘completion’ operation with the intention of disease control 
following histological confirmation of a GCC, and/or operation for treatment of imaging-identified 
disease recurrence. Details are presented in Table 4. Of the 12 patients undergoing index 
appendectomy, 8 patients underwent completion right hemicolectomy within 3 months – this includes 
one that later underwent tumour debulking with peritonectomy + HIPEC (performed at the Peritoneal 
Malignancy Unit, Basingstoke and North Hampshire Hospital, Basingstoke) for disease recurrence 
and another that underwent hysterectomy and bilateral salpingo-oophorectomy for evidence of 
residual disease at 18months post-diagnosis. One patient who underwent index appendectomy later 
underwent a small bowel resection due to evidence of metastases, as did another who had initially 
received a right hemicolectomy as their index operation. The decision to operate was on the basis of 
deemed resectability on imaging, the general condition of the patient and patient’s preference.   
Of the patients receiving appendectomy only (n=3), all had Tang A class GCC and two of them had 
G1 tumours. One patient that had a G2 (Ki 67 10%) GCC was found to harbour stage IV disease at 
first post-operative staging and died 5 months later following chemotherapy, whereas the remaining 2 
are both alive without evidence of disease at 19 and 3months follow-up, respectively. All 8 patients 
undergoing completion hemicolectomy were alive and disease free at last follow-up (median 
35.5months, range 30-121months). There was no 30-day mortality, and Clavien-Dindo [25] grade 1 
morbidity was seen in two patients. 
Serum chromogranin A and/or B were not elevated in any patients throughout follow-up, and thus 
was not useful for monitoring for disease recurrence. In the patients demonstrating disease recurrence, 
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at least one of CEA, CA 19-9 and CA 125 was elevated, however not all markers were measured in all 
patients. No evidence of disease recurrence was ever identified on 68Ga-DOTATATE PET/CT, 
whereas positive findings on 18F-FDG PET/CT were observed in all patients that had recurrent 
disease. 18F-FDG PET/CT was therefore clearly the superior imaging modality and had tangible 
ramifications on treatment strategy. For example, in one patient that underwent index appendectomy 
and then completion hemicolectomy, pathologic CA 19-9 level 12months post-hemicolectomy and 
adjuvant chemotherapy was suspicious for recurrence, which was evident on 18F-FDG PET/CT 
(Figure 1). The patient then underwent debulking, peritonectomy and HIPEC but had another 
elevation of CA 19-9 and increased uptake on 18F FDG PET/CT 12-months following this third 
intervention. (Figure 1). This patient’s peritoneal disease was Stage 3 (as per the Gilly classification) 
and her peritoneal cancer index was 12.     
The median follow-up for the cohort was 30 months (range 2.5-123 months), during which there were 
7 disease-related patient deaths, all of which had either G2 or G3 tumours. Four patients died from 
disseminated tumour recurrence within 2 years of initial treatment, all of which had received adjuvant 
chemotherapy. Median OS was not reached, whereas mean OS for the cohort was 80.3months, and 1-, 
3- and 5-year OS was 79.4%, 60% and 60%, respectively. One-, 3- and 5-year DFS was 94.7%, 
74.2% and 74.2%, respectively. Regarding Tang classification, mean OS (and 1-, 3-, and 5-year OS) 
for Tang class A, B and C tumours were 73.1 months (85.7%, 85.7%, 51.4%), 83.7 months (all 
66.7%) and 28.5 months (66.7%, 66.7%, not reached), respectively. Given the small numbers of 
patients, a comparative sub-group survival analysis was not performed.     
  
Discussion 
 
The management of patients with GCC is challenging due to a poor understanding of their biological 
behaviour, and their rarity precluding evidence-based therapeutic algorithms for optimal treatment. As 
GCC are typically diagnosed incidentally subsequent to appendectomy, the role of diagnostic 
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biomarkers is limited in this field. However, elucidation of clinically useful biomarkers for monitoring 
disease status or recurrence is a major unmet need. Whilst the limitations of chromogranin A and B in 
GCC are clearly recognised to the extent that consensus exists regarding their lack of utility in GCC 
[4], alternative markers are posited without clear evidence of sensitivity. The ENETS consensus 
guidelines of 2012 suggest CEA. CA-125 and CA 19-9 as possible markers [4]. Indeed, these were 
able to identify disease recurrence in our cohort, yet the full panel was not examined in every patient, 
and the optimal collective of assays is yet to be identified. The fact that the archetypal neuroendocrine 
markers (i.e. chromogranins) were ineffective follow-up tools, yet CEA, CA 19-9 and CA 125 were 
able to detect disease recurrence is reflective of the adenocarcinoma component of GCC driving the 
disease’s aggressive behaviour.     
Whilst recent guidelines almost universally advocate surgical therapy as the mainstay of treatment for 
GCC, there is either a lack of consensus regarding most effective surgical approach or poor quality 
data forming a basis for recommendations. As is the case with appendiceal NEN, right hemicolectomy 
may occupy a role within the treatment concept for GCC [26], yet the indications are debatable [9,27], 
which is notable given the generally appreciated increased aggressiveness of GCC compared to 
ANEN, but also the morbidity of the procedure, especially in elderly patients.   
Retrospective case series differ in their support of right hemicolectomy in localised GCC, although a 
meta-analysis by Varisco et al. including 100 patients from 13 case series with GCC failed to find a 
significant benefit of hemicolectomy relative to appendicectomy alone in this setting, and also 
reported failure rates (in terms of disease control) of appendectomy alone and extended resection of 
7% and 10%, respectively [28]. A recent institutional case series by Lamarca, et al. examined 
prognostic factors in their cohort of 74 patients wherein 64% of those treated with curative intent 
underwent right hemicolectomy [18]. The group failed to identify any effect of right hemicolectomy 
on disease-free survival - indeed their data also suggested a higher risk of relapse with right 
hemicolectomy, with relapse occurring in 50% of those receiving hemicolectomy vs. 21% of patients 
who did not (p=0.037). Furthermore, they failed to identify any specific size cut-off at which right 
hemicolectomy is associated with improved prognosis. Contrastingly, in a Danish cohort of 83 
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patients reported by Olsen, et al. [19], non-radical surgery for the primary tumour was identified as a 
negative prognosticator, and Lamarca et al. actually concluded that appendectomy alone is only 
justifiable in patients with completely resected Tang class A, stage I/II tumours that are unable to 
undergo surgery due to comorbidities conferring unacceptable surgical risk [18]. In our study, we 
followed an aggressive approach, as only three patients (all Tang class A) had received appendectomy 
alone. One of these patients died within 5months of appendectomy, and the other two were not 
candidates for further resection but remain disease-free at last follow-up. Of our 6 patients that 
received isolated completion hemicolectomy, none had displayed disease recurrence within a follow 
up of 63.5months (range 30-121 months), suggesting adequate disease control.  
Additional challenging considerations in the surgical treatment of GCC is the management of 
recurrent disease, which may involve management of the peritoneal cavity and also the use of 
prophylactic salpingo-oophorectomy in female patients. The peritoneum is the commonest site of 
metastasis, assumed to be via trans-coelomic spread, and is also the commonest site of disease relapse 
in reported series [18]. This observation has been utilised as justification by some groups for 
consideration of a staging laparoscopy [18] and consecutive cytoreductive resection with HIPEC 
[18,29], and also prophylactic bilateral salpingo-oophorectomy in female GCC patients [6,15]. Clearly 
in the latter setting, pre-menopausal women diagnosed with GCC would require careful counselling 
regarding the non-uniformly accepted benefits of disease control against infertility. In our cohort, we 
did not uniformly proceed with prophylactic oophorectomy. Three female patients identified to have 
stage IV disease at diagnosis underwent hysterectomy and/or oophorectomy, and one who initially 
underwent appendectomy with completion hemicolectomy for a stage II, G3 tumour received later 
hysterectomy and salpingo-oophorectomy due to ovarian metastases. Thus, although our data cannot 
advocate universal bilateral oophorectomy, it highlights the risk of metachronous metastases in female 
patients and call for detailed counselling with individual patients.  
The morbidity and mortality from different surgical approaches for GCC is poorly documented in the 
available literature – although a 12% rate of wound infection following cytoreductive surgery/HIPEC 
was reported by Lamarca, et al. there was no clear documentation regarding morbidity following 
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hemicolectomy [18]. We believe that the favourably low morbidity encountered in our cohort justifies 
the ‘aggressive’ approach to GCC that we are following. However, we are aware that the number of 
patients in this case series does not enable a strong recommendation. Whilst previous retrospective 
case series have analysed heterogeneous cohorts insofar as including patients undergoing both 
surgical treatment with curative intent  and palliative non-surgical treatment options, our study 
comprised patients that were all managed surgically within the course of their disease.  
The precise role and benefits of chemotherapy in GCC have not been extensively tested under the 
auspices of prospective trials. This is again attributable to the rarity of this tumour type precluding 
prospective trials of chemotherapeutics. Goblet cell carcinomas may be treated with regimens 
extrapolated from those utilised in colorectal adenocarcinomas, including FOLFOX (5-fluorouracil 
and oxaliplatin) or CAPOX (capecitabine and oxaliplatin). Such treatment selection is predicated by 
the clinical behaviour of GCC being more congruous with adenocarcinoma than with neuroendocrine 
tumour. In their series from the Mayo clinic, Pham, et al. failed to identify a significant difference in 
survival between patients undergoing adjuvant chemotherapy, and those who did not [17]. In the 
series of Lamarca et al., 18 patients underwent adjuvant chemotherapy, and 24 underwent palliative 
chemotherapy during their treatment [18]. The commonest regimen for both was FOLFOX. This 
group observed no effect of adjuvant chemotherapy on disease-free survival or relapse rate in any 
GCC stage sub-group. For palliative chemotherapy there was a 60% disease control rate, and a 14% 
rate of partial response as assessed on radiological imaging. The median estimated progression-free 
survival for palliative chemotherapy was 5.3 months. 
Overall, our study of 21 surgically-treated patients with GCC clearly demonstrates the necessity of 
treating patients with GCC in specialist centres within a multidisciplinary setting of specialist 
histopathologists, radiologists/nuclear medicine physicians, surgeons familiar with complex 
abdominal procedures and advanced technology, and oncologists. Relative to ANEN with which GCC 
was until recently often regarded as indistinct from, GCC are highly aggressive tumours and clear 
histopathological discrimination between the two is crucial. Of particular note is the rate of advanced 
disease between ANEN and GCC – in our centre, under 10% of patients with ANEN (data not 
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presented here) had nodal metastases with over 99% of ANEN G1 in nature [24], whereas 47.6% of 
our GCC patients had at least nodal metastases at initial diagnosis, and 83.3% were G2/3 tumours. 
The clear distinction between ANEN and GCC is crucial as the latter require more aggressive therapy 
and surveillance. Figure 2 demonstrates a management algorithm based on the experience from our 
centres and also the aforementioned literature.   
Despite the aggressive surgical approach in our patient cohort with most patients undergoing multiple 
surgical procedures (with/without adjuvant chemotherapy) including advanced techniques such as 
peritonectomy and HIPEC, 1-, 3- and 5-year overall survivals in our cohort were 79.4%, 60% and 
60%, respectively, and almost a fifth of patients died of disseminated tumour recurrence within 2 
years. These outcomes call for further research with an aim to better elucidate the nature of this 
disease and develop novel treatment strategies. We are aware that the small size of our cohort, the 
retrospective nature of our study and the risk of selection bias introduced by our referral pattern 
present limitations.  
Ideally, the exact role of right hemicolectomy in localised disease, the role of chemotherapy, the most 
useful follow-up protocols and also the benefits of aggressive peritoneal management in GCC would 
be elucidated by prospective trial studies. However, given the scarcity of this tumour type, such 
studies would present stark logistical challenges. Collaborative multi-centre studies of the molecular 
biology of this rare tumour type will be required to identify putative novel predictive and prognostic 
markers, and also identify targets for precision therapy in GCC.    
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Figure legends 
 
 
Figure 1. Imaging and biochemical findings in recurrent disease in a 41yr old patient with grade 3, 
Tang class C goblet cell carcinoma. The patient underwent appendectomy as the index operation, with 
completion right hemicolectomy and chemotherapy, and thereafter peritonectomy with heated intra-
peritoneal chemotherapy due to recurrence evident on biochemistry and imaging. Top (A) = 18F-FDG 
PET/CT at 12months post-hemicolectomy and chemotherapy showing multifocal recurrent disease in 
the pelvis. Central (B) = 
18
F-FDG PET/CT 12months post-peritonectomy again demonstrating pelvic 
disease recurrence. Bottom (C) = tumour marker dynamics during follow-up period – A and B 
correspond to the timing of images A and B, respectively. Red filled circles represent an elevation of 
that tumour marker.   
 
Figure 2. Algorithm for the management of patients with goblet cell carcinomas. HIPEC = heated 
intra-peritoneal chemotherapy.  
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Figure 2. Suggested algorithm for the management of patients with goblet cell carcinoma 
 Diagnosis of GCC 
Recurrent disease, resectable: 
Peritoneal ± consider HIPEC 
Other resection based on site of recurrence 
No recurrence: 
Continue 
surveillance 
Follow-up: 
3-6monthly: CA19-9, CA-15 and CEA, consider 
morphological imaging with CT/MRI 
12monthly: 18F-FDG PET/CT (or earlier if suspicion of 
recurrence, e.g. on cross-sectional imaging) 
Consider adjuvant chemotherapy (i.e. 
FOLFOX) if: 
Stage II or Tang B/C primary tumour 
Stage III/IV treated with curative intent 
Index operation 
Recurrent disease, non-
resectable 
Palliative chemotherapy  
If right hemicolectomy: 
Discuss bilateral salpingo-oophorectomy 
in females   
If appendectomy: 
Proceed to oncological right 
hemicolectomy within 3 months 
unless not a surgical candidate (i.e. 
precluded by co-morbidities) 
Immunohistochemistry; CA19-9, CA-125 and CEA; disease staging with CT, and 18F-FDG PET/CT 
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Component Criterion 
Primary tumour  
T0 No tumour evident 
T1a Tumour ≤1cm in greatest dimension 
T1b Tumour >1cm but ≤2cm in greatest dimension 
T2 Tumour >2cm but ≤4cm, or with extension into the 
caecum 
T3 Tumour >4cm, or with extension into the ileum 
T4 Tumour perforates peritoneum or invades other 
adjacent structures 
Regional lymph node metastases  
N0 None present 
N1 Present 
Distant metastases   
M0 None present 
M1 Present 
 
  
Table 1. TNM staging system for goblet cell carcinomas of the appendix as per the UICC/AJCC 
guidelines [4] – these are identical to those for appendiceal neuroendocrine neoplasms.  
UICC/AJCC stage    
I T1 N0 M0 
II T2-3 N0 M0 
III T4 
Any T 
N0 
N1 
M0 
M0 
IV Any T Any N M1 
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Tang class Designation Characteristics 
A Typical GCC Well defined goblet cells (clusters or linear) with minimal atypia 
Minimal or no desmoplasia 
Minimal distortion of appendiceal wall 
B Adenocarcinoma ex-GCC, 
signet cell type 
Goblet or signet ring-type cells in large, irregular clusters 
Single file or single cell infiltrative pattern 
Significant atypia  
Desmoplasia evident with destruction of appendiceal wall 
C Adenocarcinoma ex-GCC, 
poorly differentiated carcinoma 
type 
Minimum of focal evidence of goblet cell morphology 
A component indistinguishable from poorly differentiated adenocarcinoma (e.g. gland-
forming, confluent sheets of signet ring cells) 
 
 
Table 2. Histopathological (Tang) classification of goblet cell carcinomas adapted from that as proposed by Tang, et al. [15]. GCC = goblet cell carcinoma.  
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Parameter N  
Gender 
          Male 
          Female 
 
9  
12 
Median age at diagnosis (range) 55 (32-77) 
Tumour grade 
A, B 
          G1 
          G2 
          G3 
 
3/18 
6 /18 
9 /18 
Tumour stage at diagnosis B 
          I 
          II 
          III 
          IV 
 
1  
10 
5  
5  
Tumour location within appendix 
C
 
         Base 
         Body 
         Tip 
 
10/18  
5 / 18  
3/ 18  
Tang classification 
E
 
          A 
          B 
          C            
 
8  
10  
3  
 
  
Table 3.  Clinicopathological characteristics of the study cohort (n=21). A+C = data available for 18 
18 patients; B = as per ENETS guidelines [4]; D = as per AJCC/UICC system [4]; E = as per Tang, et 
al. [15].   
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 Table 4. Operative characteristics and follow-up for the cohort (n=21). HIPEC = hyperthermic intra-peritoneal chemotherapy, A = alive, NED = no evidence 
of disease at last follow-up, DOD = died of disease, DR = disease recurred, *= recurrence at 18months, but disease free at last follow-up.  
Patient number Age at diagnosis Index operation Adjuvant 
chemotherapy 
Completion  
operation 
Surgery for tumour 
recurrence  
 
Follow-up length 
months 
Status at last 
follow-up 
1 77 Right hemicolectomy    123 A, NED 
2 71 Appendectomy Yes   5 DOD 
3 36 Appendectomy  Right hemicolectomy  51 A, NED 
4 56 Appendectomy  Right hemicolectomy  121 A, NED 
5 58 Appendectomy  Right hemicolectomy  73 A, NED 
6 64 Appendectomy + 
hysterectomy + omentectomy 
+ oophorectomy 
Yes   30 DOD 
7 32 Appendectomy  Right hemicolectomy  34 A, NED 
8 67 Appendectomy  Right hemicolectomy Hysterectomy + bilateral 
salpingo-oophorectmy 
31 A, NED 
9 68 Right hemicolectomy Yes   7 DOD 
10 41 Appendectomy  Right hemicolectomy Peritonectomy + HIPEC 37 A, NED* 
11 45 Right hemicolectomy Yes   2.5 DOD 
12 51 Appendectomy  Right hemicolectomy  30 A, NED 
13 67 Appendectomy    Small bowel resection 28 A, NED 
14 49 Appendectomy  Right hemicolectomy  38 A, NED 
15 39 Right hemicolectomy + 
omentectomy + uterine 
resection 
Yes   6 DOD 
16 44 Appendectomy + 
omentectomy + oophorectomy 
   27 DOD 
17 61 Right hemicolectomy   Small bowel resection 54 A, DR 
18 37 Appendectomy Yes   19 A, NED 
19 60 Right hemicolectomy    32 DOD 
20 50 Appendectomy    3 A, NED 
21 55 Right hemicolectomy    4 A, NED 
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